Effects of rosuvastatin combined with garlic extract on patients of pulmonary hypertension: A random, controlled trial.

Effifcacy of rosuvastatin combined with garlic extract on patients of pulmonary hypertension: A random, controlled trial.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-17011827

Enrollment

Unknown

Registered

2017-07-02

Start date

2017-07-01

Completion date

Unknown

Last updated

2017-07-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pulmonary hypertension

Interventions

control 1:rosuvastatin oral based on routine treatment

control 2:garlic extract oral based on routine treatment

experimental group:rosuvastatin combined with garlic extract oral based on routine treatment

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. aged 45 to 70 years old, men and women; 2. diagosed as pulmonary hypertension (PH) by at least two visiting staff, on basis of medical history, symptom and sign; 3. rate of tricuspid regurgitation =2.8 m/sthat is systolic pressure =36mmHg, detected by Echocardiography; 4. the ERS/ESC classification in 2015 patients with 1, 3, 4 class period, include: pulmonary arterial hypertension, PH due to lung diseases and chronic thromboembolic PH; 5. serum cholesterol >5.72 mmol/L; 6. MWDS baseline acuity 100 m and 450 m; 7. the participants or their guardians agree to participate in this test, and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. allergic to medicine of this trial; 2. doubt or have alcohol and drug abuse history; 3. during pregnancy and lactation women; 4. involved in any clinical trial in recent 3 months; 5. unstable angina pectoris or myocardial infarction in recent 1 month; 6. NYHA classification IV; 7. severe lung infection; 8. serum total bilirubin, AST or ALT 1.5 times more than upper limit of normal; 9. Ccr =50ml/min; 10.cannot fulfill 6 min walking distance testing; 11.severe bleeding tendency, such as active peptic ulcer, intracranial hemorrhage, trauma, or other bleeding; 12.decline to comply with the rules of this trial; 13.any other person.was not fit for this trial judged by researchers.

Design outcomes

Primary

Measure	Time frame
6-minute walk test(6-MWT);Echocardiography;pulmonary function test;	—

Countries

China

Contacts

Public ContactWeibing Yang

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

wbingyang@qq.com+86 027 85726707

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026